Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar | NEJM

Compared to the primary series, booster effectiveness against symptomatic omicron infection was 49.4%, with the primary series 76.5%.

https://www.nejm.org/doi/full/10.1056/NEJMoa2200797